3 Things You Need to Know
Standard of care
Is of the essence
Patricia: Clinical Trial Patient
When Patricia’s glioblastoma came back after her first surgery, she and her husband both knew it was time to start looking at alternative treatment options. After extensive research, they discovered the hope they were looking for was actually right in their backyard at the Ivy Center in Phoenix.
Tumors We Treat
Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma
Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body
Primary brain tumors derived from the lining of the brain, known as the meninges
Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord
Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve
Occurs in the pineal region of the brain that may or may not involve the pineal gland
COMMUNITY OF CAREGIVERS
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.